Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
24 December 2024 - 1:20AM
Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”)
(NASDAQ: SONN), a clinical-stage company developing targeted
immunotherapeutic drugs, today announced the next CEO Corner
segment has been published on the Company’s website.
As part of the CEO Corner segment, Pankaj Mohan,
Ph.D., Founder and Chief Executive Officer of Sonnet, highlighted
the Company’s key accomplishments for calendar year 2024 and the
targeted value-driving milestones in calendar year 2025.
The CEO Corner is now accessible on the
Company’s website here. Segments on the CEO Corner platform will be
accessible on the Company’s website (www.sonnetbio.com) for 90
days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused
biotechnology company with a proprietary platform for innovating
biologic drugs of single or bifunctional action. Known as FHAB
(Fully Human Albumin Binding), the technology utilizes a fully
human single chain antibody fragment (scFv) that binds to and
"hitch-hikes" on human serum albumin (HSA) for transport to target
tissues. Sonnet's FHAB was designed to specifically target tumor
and lymphatic tissue, with an improved therapeutic window for
optimizing the safety and efficacy of immune modulating biologic
drugs. FHAB is the foundation of a modular, plug-and-play construct
for potentiating a range of large molecule therapeutic classes,
including cytokines, peptides, antibodies, and vaccines.
Investor Relations Contact:JTC Team, LLCJenene
Thomas 908.824.0775SONN@jtcir.com
Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Dec 2023 to Dec 2024